New Guidance Published in Eudralex Volume 10 - Clinical Trials
|
GMP News |
|
New Guidance Published in Eudralex Volume 10 – Clinical Trials |
|
As the European Commission points out in the document's introduction, it "intends to clarify and provide additional guidance on the definition of investigational medicinal products and to provide specific guidance about the use of non-investigational medicinal products, in accordance with the applicable EU legislation. The Guidance complements the "Detailed guidance for the request for authorisation of a clinical trial on a medicinal product for human use to the competent authorities, notification of substantial amendments and declaration of the end of the trial"1 and the "Detailed guidance on the application format and documentation to be submitted in an application for an Ethics Committee opinion on the clinical trial on medicinal products for human use". Besides clarification on how an IMP is defined, the
document also gives general guidance on other medicinal products used in
clinical trials like for example concomitant or rescue/escape medication for
preventive, diagnostic or therapeutic reasons and/or to ensure that adequate
medical care is provided. Guidance is also given on medicinal products which
are normally used in clinical trials as non-investigational medicinal
products (NIMPs). |
|
Hear essential aspects about the organisation and management of clinical trials, IMP distribution and things to consider during the study in the ECA Education Course
During this course, the important interfaces between GMP and GCP will be elaborated. |
|
|
GMP Conferences by Topics
- Quality Assurance
- GMP in Biotechnology
- Microbiology
- Regulatory Affairs
- GMP in Pharmaceutical Development
- Quality Control
- GDP
- Sterile / Aseptic Manufacturing
- Computer Validation
- Validation
- Technical Operations
- GMP for APIs and Excipients
- Medical Devices
- GMP Basic Training Courses
- Packaging
- Data Integrity